Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Metabolism
  4. Volume 25, Issue 7
  5. Article
Volume 25, Issue 7
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453

Abstract

Introduction

Limited data exist on therapeutic ranges for newer antimicrobials in the critically ill, with few pharmacokinetic studies including patients undergoing renal replacement therapy or extracorporeal membrane oxygenation (ECMO).

Case Representation

These interventions can potentially alter the pharmacokinetic profile of antibiotics, resulting in therapeutic failures, antimicrobial resistance, or increased toxicity. In this report, we present two ECMO patients treated with cefiderocol and ceftobiprole, where therapeutic drug monitoring (TDM) aided in the successful treatment of severe infections. Antibiotic trough concentrations in both cases were consistent with previously reported therapeutic levels in critically ill and ECMO patients, meeting minimal inhibitory concentrations recommended by the European Committee on Antimicrobial Susceptibility Testing for the respective pathogens.

Conclusion

Treatment might be suboptimal if doses are not adjusted based on physicochemical properties and extracorporeal support. In an era marked by highly resistant pathogens, these cases highlight the importance of timely access to real-time TDM for optimizing and individualizing antimicrobial treatment.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdm/10.2174/0113892002331260240919055056
2024-09-27
2025-01-10

  • From This Site

    /content/journals/cdm/10.2174/0113892002331260240919055056
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BassettiM. MularoniA. GiacobbeD.R. CastaldoN. VenaA. New Antibiotics for hospital-acquired pneumonia and ventilator-associated pneumonia.Semin. Respir. Crit. Care Med.202243228029410.1055/s‑0041‑174060535088403
     [Google Scholar]
  2. SimnerP.J. PatelR. Cefiderocol antimicrobial susceptibility testing considerations: The achilles’ heel of the trojan horse?J. Clin. Microbiol.2020591e00951-2010.1128/JCM.00951‑2032727829
     [Google Scholar]
  3. WangC. YangD. WangY. NiW. Cefiderocol for the treatment of multidrug-resistant gram-negative bacteria: A systematic review of currently available evidence.Front. Pharmacol.20221389697110.3389/fphar.2022.89697135496290
     [Google Scholar]
  4. Abdul-AzizM.H. AlffenaarJ.W.C. BassettiM. BrachtH. DimopoulosG. MarriottD. NeelyM.N. PaivaJ.A. PeaF. SjovallF. TimsitJ.F. UdyA.A. WichaS.G. ZeitlingerM. De WaeleJ.J. RobertsJ.A. Antimicrobial therapeutic drug monitoring in critically ill adult patients: A position paper.Intensive Care Med.20204661127115310.1007/s00134‑020‑06050‑132383061
     [Google Scholar]
  5. Morales CastroD. DresserL. GrantonJ. FanE. Pharmacokinetic alterations associated with critical illness.Clin. Pharmacokinet.202362220922010.1007/s40262‑023‑01213‑x36732476
     [Google Scholar]
  6. SmithB.S. YogaratnamD. Levasseur-FranklinK.E. ForniA. FongJ. Introduction to drug pharmacokinetics in the critically ill patient.Chest201214151327133610.1378/chest.11‑139622553267
     [Google Scholar]
  7. BoucherB.A. WoodG.C. SwansonJ.M. Pharmacokinetic changes in critical illness.Crit. Care Clin.2006222255271, vi10.1016/j.ccc.2006.02.01116677999
     [Google Scholar]
  8. ZimmerJ. RöhrA.C. KlugeS. FallerJ. FreyO.R. WichmannD. KönigC. Validation and application of an HPLC-UV method for routine therapeutic drug monitoring of cefiderocol.Antibiotics (Basel)202110324210.3390/antibiotics1003024233670891
     [Google Scholar]
  9. LlopisB. BleibtreuA. SchlemmerD. RobidouP. PaccoudO. TissotN. NoéG. JunotH. LuytC.É. Funck-BrentanoC. ZahrN. Simple and accurate quantitative analysis of cefiderocol and ceftobiprole in human plasma using liquid chromatography-isotope dilution tandem mass spectrometry: Interest for their therapeutic drug monitoring and pharmacokinetic studies.Clin. Chem. Lab. Med.202159111800181010.1515/cclm‑2021‑042334243226
     [Google Scholar]
  10. RobertsJ.A. BellomoR. CottaM.O. KochB.C.P. LysterH. OstermannM. RogerC. ShekarK. WattK. Abdul-AzizM.H. Machines that help machines to help patients: Optimising antimicrobial dosing in patients receiving extracorporeal membrane oxygenation and renal replacement therapy using dosing software.Intensive Care Med.202248101338135110.1007/s00134‑022‑06847‑235997793
     [Google Scholar]
  11. ShekarK. FraserJ.F. SmithM.T. RobertsJ.A. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation.J. Crit. Care.2012276741.e91810.1016/j.jcrc.2012.02.013.
     [Google Scholar]
  12. ChengV. Abdul-AzizM.H. RobertsJ.A. ShekarK. Overcoming barriers to optimal drug dosing during ECMO in critically ill adult patients.Expert Opin. Drug Metab. Toxicol.201915210311210.1080/17425255.2019.156359630582435
     [Google Scholar]
  13. DzierbaA.L. AbramsD. BrodieD. Medicating patients during extracorporeal membrane oxygenation: the evidence is building.Crit. Care20172116610.1186/s13054‑017‑1644‑y28320466
     [Google Scholar]
  14. BougléA. DujardinO. LepèreV. Ait HamouN. VidalC. LebretonG. SalemJ.E. El-HelaliN. PetijeanG. AmourJ. Pharmecmo: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on extracorporeal life support.Anaesth. Crit. Care Pain Med.201938549349710.1016/j.accpm.2019.02.01530831307
     [Google Scholar]
  15. ChengV. Abdul-AzizM.H. RobertsJ.A. ShekarK. Optimising drug dosing in patients receiving extracorporeal membrane oxygenation.J. Thorac. Dis.201810S5S629S64110.21037/jtd.2017.09.15429732181
     [Google Scholar]
  16. DonadelloK. AntonucciE. CristalliniS. RobertsJ.A. BeumierM. ScollettaS. JacobsF. RondeletB. de BackerD. VincentJ.L. TacconeF.S. β-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case–control study.Int. J. Antimicrob. Agents201545327828210.1016/j.ijantimicag.2014.11.00525542059
     [Google Scholar]
  17. BerryA.V. ConeliusA. GluckJ.A. NicolauD.P. KutiJ.L. Cefiderocol is Not Sequestered in an Ex Vivo Extracorporeal Membrane Oxygenation (ECMO) Circuit.Eur. J. Drug Metab. Pharmacokinet.202348443744110.1007/s13318‑023‑00840‑w37351777
     [Google Scholar]
  18. BakdachD. ElajezR. BakdachA.R. AwaisuA. De PascaleG. Ait HssainA. Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation.J. Clin. Med.20221123689810.3390/jcm1123689836498473
     [Google Scholar]
  19. TorresA. MoutonJ.W. PeaF. Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations.Clin. Pharmacokinet.201655121507152010.1007/s40262‑016‑0418‑z27272266
     [Google Scholar]
  20. GiacobbeD.R. De RosaF.G. Del BonoV. GrossiP.A. PeaF. PetrosilloN. RossoliniG.M. TasciniC. TumbarelloM. VialeP. BassettiM. Ceftobiprole: drug evaluation and place in therapy.Expert Rev. Anti Infect. Ther.201917968969810.1080/14787210.2019.166722931553250
     [Google Scholar]
  21. Santerre HenriksenA. SmartJ.I. HamedK. Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015.Infect. Drug Resist.2018111309132010.2147/IDR.S17636930214251
     [Google Scholar]
  22. KönigC. BothA. RohdeH. KlugeS. FreyO.R. RöhrA.C. WichmannD. Cefiderocol in critically Ill patients with multi-drug resistant pathogens: Real-life data on pharmacokinetics and microbiological surveillance.Antibiotics (Basel)202110664910.3390/antibiotics1006064934071700
     [Google Scholar]
  23. FalconeM. TiseoG. NicastroM. LeonildiA. VecchioneA. CasellaC. ForforiF. MalacarneP. GuarracinoF. BarniniS. MenichettiF. Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant gram-negative infections in intensive care unit patients.Clin. Infect. Dis.202172112021202410.1093/cid/ciaa141032941593
     [Google Scholar]
  24. Borsuk-De MoorA. RypulakE. PotręćB. PiwowarczykP. BorysM. SysiakJ. OnichimowskiD. RaszewskiG. CzuczwarM. WiczlingP. Population pharmacokinetics of high-dose tigecycline in patients with sepsis or septic shock.Antimicrob. Agents Chemother.2018624e02273-1710.1128/AAC.02273‑1729358291
     [Google Scholar]
  25. RieraJ. DomenechL. GarcíaS. PauA. SosaM. DomenechJ. PalmadaC. TorrellaP. SánchezA. LamoraA. GallartE. GirónP. NuvialsX. FerrerR. Pharmacokinetics of cefiderocol during extracorporeal membrane oxygenation: A case report.Perfusion2023381_suppl404310.1177/0267659123116046236853601
     [Google Scholar]
  26. KatsubeT. EcholsR. WajimaT. Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin.Clin. Infect. Dis.201969S552S55810.1093/cid/ciz82831724042
     [Google Scholar]
  27. ShekarK. Abdul-AzizM.H. ChengV. BurrowsF. BuscherH. ChoY.J. CorleyA. DiehlA. GilderE. JakobS.M. Antimicrobial exposures in critically Ill patients receiving extracorporeal membrane oxygenation.Am J Respir Crit Care Med2023207670477010.1164/rccm.202207‑1393OC.
     [Google Scholar]
  28. CoppensA. ZahrN. ChommelouxJ. BleibtreuA. HekimianG. Pineton de ChambrunM. LeFevreL. SchmidtM. RobertJ. JunotH. CombesA. LuytC.E. Pharmacokinetics/pharmacodynamics of ceftobiprole in patients on extracorporeal membrane oxygenation.Int. J. Antimicrob. Agents202361410676510.1016/j.ijantimicag.2023.10676536804372
     [Google Scholar]
  29. VialeP. SandrockC.E. RamirezP. RossoliniG.M. LodiseT.P. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.Ann. Intensive Care20231315210.1186/s13613‑023‑01146‑537322293
     [Google Scholar]
  30. BookeH. FriedrichsonB. DraheimL. von GrooteT.C. FreyO. RöhrA. ZacharowskiK. AdamE.H. No sequestration of commonly used anti-infectives in the extracorporeal membrane oxygenation (ECMO) circuit—an Ex vivo study.Antibiotics (Basel)202413437310.3390/antibiotics1304037338667049
     [Google Scholar]
  31. MercadanteS. TripicianoC. RomaniL. Di NardoM. BottariG. GoffredoB.M. SimeoliR. GuzzoI. LancellaL. AntachopoulosC. De LucaM. The use of cefiderocol as salvage therapy in an infant receiving ECMO and continuous renal replacement therapy.Antibiotics (Basel)20231313710.3390/antibiotics1301003738247596
     [Google Scholar]
  32. WickyP.H. PoiraudJ. AlvesM. PatrierJ. d’HumièresC. LêM. KramerL. de MontmollinÉ. MassiasL. Armand-LefèvreL. TimsitJ.F. Cefiderocol treatment for severe infections due to difficult-to-treat-resistant non-fermentative gram-negative bacilli in ICU patients: A case series and narrative literature review.Antibiotics (Basel)202312699110.3390/antibiotics1206099137370310
     [Google Scholar]
  33. GattiM. BartolettiM. CojuttiP.G. GaibaniP. ContiM. GiannellaM. VialeP. PeaF. A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol.J. Glob. Antimicrob. Resist.20212729429810.1016/j.jgar.2021.10.01434710630
     [Google Scholar]
  34. CojuttiP.G. MerelliM. De StefanisP. FregoneseC. LuccheseF. BassettiM. PeaF. Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient.Eur. J. Clin. Pharmacol.201874121671167210.1007/s00228‑018‑2535‑030094703
     [Google Scholar]
  35. LysterH. ShekarK. WattK. ReedA. RobertsJ.A. Abdul-AzizM.H. Antifungal dosing in critically Ill patients on extracorporeal membrane oxygenation.Clin. Pharmacokinet.202362793194210.1007/s40262‑023‑01264‑037300631
     [Google Scholar]
  36. Abdul-AzizM.H. RobertsJ.A. Antibiotic dosing during extracorporeal membrane oxygenation: Does the system matter?Curr. Opin. Anaesthesiol.2020331718210.1097/ACO.000000000000081031764007
     [Google Scholar]
  37. WongG. BriscoeS. McWhinneyB. AllyM. UngererJ. LipmanJ. RobertsJ.A. Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: Direct measurement of unbound drug concentrations to achieve appropriate drug exposures.J. Antimicrob. Chemother.201873113087309410.1093/jac/dky31430137377
     [Google Scholar]
  38. KühnD. MetzC. SeilerF. WehrfritzH. RothS. AlqudrahM. BeckerA. BrachtH. WagenpfeilS. HoffmannM. BalsR. HübnerU. GeiselJ. LepperP.M. BeckerS.L. Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: A prospective, observational single-center study.Crit. Care202024166410.1186/s13054‑020‑03397‑133239110
     [Google Scholar]
  39. Abdul-AzizM. LipmanJ. MoutonJ. HopeW. RobertsJ. Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: Optimizing efficacy and reducing resistance development.Semin. Respir. Crit. Care Med.201536113615310.1055/s‑0034‑139849025643277
     [Google Scholar]
  40. DuceppeM.A. KanjiS. DoA.T. RuoN. CavayasY.A. AlbertM. Robert-HalabiM. ZavalkoffS. DupontP. SamoukovicG. WilliamsonD.R. Pharmacokinetics of commonly used antimicrobials in critically ill adults during extracorporeal membrane oxygenation: A systematic review.Drugs202181111307132910.1007/s40265‑021‑01557‑334224115
     [Google Scholar]
  41. KrieglL. HatzlS. SchilcherG. Zollner-SchwetzI. BoyerJ. GeigerC. HoeniglM. KrauseR. Antifungals in patients with extracorporeal membrane oxygenation: Clinical implications.Open Forum Infect. Dis.2024116ofae27010.1093/ofid/ofae27038887481
     [Google Scholar]
/content/journals/cdm/10.2174/0113892002331260240919055056
Loading

  • Article Type:     Case Report
Keyword(s): Antibiotics; drug resistance; extracorporeal membrane oxygenation; MDR; renal replacement therapy; therapeutic drug monitoring

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test